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compared with DT.
CONCLUSIONS The degree of coronary artery lesions appears to have
some correlation with ID, IT, DT and IT/DT. High doses of insulin or
high ratio IT/DT may aggravate coronary artery damage.GW26-e2122
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OBJECTIVES To investigate the relationship between hemoglobin A1c
(HbA1c) and left atrial thrombus or left atrial spontaneous echo
contrast (LATH/SEC) in non-valvular atrial ﬁbrillation (NVAF)
patients.
METHODS We enrolled 1158 patients with NVAF who underwent
transesophageal echocardiography (TEE) prior to radiofrequency
catheter ablation, left atrial appendage closure or electric cardiover-
sion at Guangdong Cardiovascular Institute. Data on clinical baseline
characteristic of all the patients were collected from electronic med-
ical records and analyzed.
RESULTS There were 87 NVAF patients with LATH/SEC. The mean
HbA1c was signiﬁcantly higher in NVAF patients with LATH/SEC
(6.130.41% vs. 5.880.45%, P<0.001). Receiver operating charac-
teristic (ROC) curve was presented by HbA1c, which indicated area
under curve was 0.706 (95% Conﬁdence Interval: 0.679-0.732,
P<0.001) and the best HbA1c cut-point was 6.1%. In multivariate lo-
gistic regression analysis, after adjustment for persistent/paroxysmal
AF, age, heart failure, previous stroke, gender and vascular disease,
HbA1c6.1% (Odds Ratio: 2.207, 95%Conﬁdence Interval: 1.306-3.731,
P¼0.003) and diabetes mellitus (Odds Ratio: 1.766, 95%Conﬁdence
Interval: 1.002-3.113, P¼0.049) were independent risk factors for
LATH/SEC.
CONCLUSIONS The mean HbA1c was signiﬁcantly higher in NVAF
patients with LATH/SEC. HbA1c6.1% was an independent risk factor
for LATH/SEC in patients with NVAF. Compared with diabetes melli-
tus, HbA1c6.1% might offer more favorable predictive value on
LATH/SEC.DIABETES
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OBJECTIVES Glycometabolic disturbances have been associated
with increased mortality in patients with acute coronary syndrome
(ACS). However, the predictive value of glycemic variability (GV)
for short-term adverse outcome in diabetic patients after percuta-
neous coronary intervention (PCI) is not clear. The aim of this study
is to investigate the prognostic value of in-hospital GV and hemo-
globin A1c (HbA1c) for 3 months major adverse cardiac events
(MACE) in diabetic patients with unstable angina (UA) undergoing
PCI.
METHODS We studied 459 diabetic patients with UA, whose clinical
data including the global registry of acute coronary events (GRACE)
risk score, GV and HbA1c were collected before elective percuta-
neous coronary intervention (PCI). The GV accessed by mean
amplitude of glycemic excursions (MAGE) in patients were
measured by a continuous glucose monitoring system (CGMS) for72 hours. The MAGE was calculated by measuring the arithmetic
mean of the differences between consecutive peaks and nadirs,
provided that the differences are greater than one standard devia-
tion (SD) of the mean glucose value. Patients were categorized ac-
cording to MAGE level (<3.9 and 3.9 mmol/L), based on reference
values for continuous glucose monitoring in Chinese subjects, and
according to HbA1c level (<6.5% and 6.5%). The MACE of patients
was documented during 3 months follow-up. During follow-up
period, incidences of MACE were registered, including new-onset
myocardial infarction, recurrent angina, repeat target vessel revas-
cularization (TVR) after initial revascularization and cardiac death.
The relationship of MAGE and incidence of MACE in diabetic pa-
tients with UA was analyzed.
RESULTS In all participants, a higher MAGE level or a higher HbA1c
level was associated with the higher GRACE score (r¼0.191, r¼0.165,
all p<0.001). The rate of short-term MACE in high MAGE group was
higher than in low MAGE group (12.4% vs. 4.8%, p¼0.005), and it is
similar between high HbA1c group and low HbA1c group (10.0% vs.
5.8%, p ¼ 0.112). Patients with a higher MAGE level had a signiﬁ-
cantly higher cardiac mortality during 3 months follow-up (1.8% vs.
0%, p ¼ 0.049). The rates of cardiac mortality, repeat infarction,
recurrent angina and TVR in high HbA1c group were similar
compared with low HbA1c group (all p > 0.05). Kaplan-Meier sur-
vival curve analysis showed the incidence of MACE was signiﬁ-
cantly higher in the high MAGE level group (log-rank test, p ¼
0.003). There is a trend toward lower event-free survival rate in
high HbA1c level patients, but the difference is not signiﬁcant (log-
rank test, p ¼ 0.099). In multivariable analysis, high MAGE level
(HR 2.994, 95% CI 1.368-6.579, p¼0.006) was signiﬁcantly associ-
ated with incidence of short-term MACE even after adjusting for
GRACE risk score, but HbA1c (HR 1.592, 95% CI 0.708-3.584,
p¼0.261) was not.
CONCLUSIONS The in-hospital glycemic variability may be a power-
ful predictor of increased short-term MACE and mortality in diabetic
patients with UA following PCI.GW26-e2477
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OBJECTIVES Women with gestational diabetes mellitus (GDM) have
high rates of pregnancy complications. The aim of this study was to
estimate the impact of GDM on pregnant, obstetric and neonatal
outcomes, and to evaluate whether the risk of serious perinatal out-
comes has changed.
METHODS A retrospective double cohort study (3695 participants in
2001; 7428 in 2010) was performed among women who gave birth in
Shanghai First Maternity and Infant Hospital and Shanghai Tenth
People’s Hospital between Jan 1th to Dec 31th in 2001 and 2010. Cox
regression model was conducted to explore the relationship between
GDM and adverse perinatal outcomes.
RESULTS GDM pregnant women had lower values of both body
mass index (23.393.26kg/m2) and hemoglobin (105.6013.48g/L) in
2010 than those (25.104.00kg/m2, 119.2032.89g/L) in 2001 during
their ﬁrst prenatal visit, with an earlier gestational week of ﬁrst
prenatal visit (16.824.62w). Weight gains of GDM women were
controlled in normal range, with the timepoint of diagnose to GDM
being earlier in 2010 than 2001. As shown in Cox regression models,
after adjusted for maternal age, parity, history of spontaneous
abortion, history of ectopic pregnancy, unknown stillbirth and dead
fetal history and family history of diabetes, GDM increased the risk
of adverse outcomes that included macrosomia, hydramnios, Large
for gestational age (LGA), hypertensive disorders complicating
pregnancy(HDP) and cesarean delivery in the model of 2001. The
risk ratio (RR) and 95% conﬁdence interval (CI) were 5.82(3.33-
10.16), 4.48(1.24-16.23), 2.47(1.75-3.48), 2.32(1.01-5.33), 2.15(1.73-
2.68), respectively. Adding moderator variable (body mass index,
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model, GDM increased the risk of adverse outcomes that included
neonatal intensive care unit (NICU), macrosomia, HDP, LGA, pre-
mature delivery and cesarean delivery in the model of 2010. The
value of adjusted RR (95%CI) were: 2.38(1.36-4.18), 2.13 (1.48-3.07),
2.01(1.17-3.46), 1.67 (1.36-2.04), 1.48(1.02-2.15), 1.44 (1.26-1.63),
respectively. The incidence of adverse maternal outcomes of GDM
subjects in 2010 (78.50%) was less than that (94.68%) in 2001
(X2¼13.22, P<0.01).
CONCLUSIONS GDM had a close relationship with adverse perinatal
outcomes in both 2001 and 2010. The rank of above outcomes had
changed in different stages, with the most serious outcome being
macrosomia in 2001 and NICU in 2010. Although the maternal out-
comes have improved over the past 10 years, further efforts are
needed to reduce adverse neonatal outcomes.GW26-e4793
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OBJECTIVES The systematic review was to assess the comparative
effects of GLP-1 RAs on glycemic control, hypoglycemia and treatment
discontinuation for treating type 2 diabetes.
METHODS We searched MEDLINE, EMBASE, the Cochrane library,
and www.clinicaltrials.gov from inception to June 1, 2014. Ran-
domized controlled trials comparing a GLP-1 RA with placebo, active
anti-diabetic drugs, or other kinds of GLP-1 RAs for type 2 diabetes
were included. We only considered the doses of GLP-1 RAs used in
routine clinical practice. Eligible trials should have available data on
the outcomes of HbA1c <7%, hypoglycemia or treatment discon-
tinuation, with the follow-up of at least 8 weeks. The revised
JADAD scale was used to assess risk of bias of the included studies.
Network meta-analysis using multivariate model with multi-arm
trials adjusted was conducted. We applied loop-speciﬁc approach to
test the assumption of consistency. Ranking of treatment effects
was based on probability shown by the surface under the cumula-
tive ranking curve.
RESULTS From a total of 1139 retrieved records, 78 eligible trials
with 34,685 patients were included. 13 different treatments
compared in the network included daily exenatide, weekly exena-
tide, liraglutide, albiglutide, taspoglutide, lixisenatide, dulaglutide,
sitagliptin, insulin, thiazolidinedione, sulphanylureas, metformin,
and Placebo. The mean and standard deviation of JADAD scores was
5.60 and 1.36, indicating overall low risk of bias of the trials. No
signiﬁcant differences were found on the outcome of HbA1c<7%
between any of GLP-1 RAs and any of traditional anti-diabetes
treatments. However, daily exenatide, liraglutide, taspoglutide and
lixisenatide induced signiﬁcantly less hypoglycemia (odds ratio
(95%CI): 0.63 (0.43, 0.93), 0.42 (0.25, 0.71), 0.43 (0.23, 0.81), 0.43
(0.22, 0.81), respectively) but signiﬁcantly higher treatment
discontinuation (odds ratio (95%CI): 2.50 (1.33, 5.00), 2.42 (1.29,
4.78), 5.51 (2.71, 12.08), 2.28 (1.02, 5.32), respectively) than insulin.
Compared with sulphanylureas there was signiﬁcant reduction in
hypoglycemia but higher discontinuation in GLP-1 RAs. Any of the
GLP-1 RAs had similar odds of hypoglycemia or discontinuation to
metformin. Weekly exenatide ranked top on the outcome of
HbA1c <7%, sulphanylureas and taspoglutide may have the most
serious problem on hypoglycemia and treatment discontinuation
respectively. 13.7% (10/73), 1.5% (2/128) and 13.4% (7/52) loops
were inconsistent respectively for the outcome of HbA1c <7%,
hypoglycemia and treatment discontinuation, suggesting overall
consistency.
CONCLUSIONS GLP-1 RAs may have similar efﬁcacy of lowering
HbA1c to traditional anti-diabetes treatments and probably induce
less hypoglycemia and higher treatment discontinuation. Insufﬁcient
number of trials in some pairwise comparisons may produce statistical
inconsistency and uncertainty of the results, which require further
robust evidence from well-designed trials.GW26-e1839
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OBJECTIVES Exercise is considered a protective factor in the pre-
vention of type 2 diabetes (T2D), though its role as a sole treatment for
pre-diabetes remains unknown. The present meta-analysis compares
the effect of exercise-only to exercise-diet interventions on plasma
glucose levels among a pre-diabetic population.
METHODS A literature search using PUBMED, EMBASE and
COCHRANE databases yielded 12 studies for analysis. Cochrane Col-
laborations tool and the Jadad scale were used to assess the quality of
the included articles. A random effects model was used to calculate
the pooled effect. Weighted mean difference (WMD) was calculated to
indicate the change of fast glucose level. Meta-regression was un-
dertaken to explore the impact of risk of bias for the included studies
and the forest plot was conducted to explore the relationship between
interventions.
RESULTS A total of 4,021 subjects were included in the analysis,
2,045 of them in the intervention group and 1,976 in the control
group. Compared to the exercise-only interventions, the exercise-
diet interventions showed a signiﬁcant effect on decreasing fasting
plasma glucose (Z¼12.06, P<0.05). The subgroup effect of exercise-
only interventions did not produce a statistically signiﬁcant result
(Z¼1.91, P>0.05), however, it still revealed a clinically signiﬁcant
decrease in fasting plasma glucose(WMD¼-0.19, 95%CI:-0.18,0.00).
According to four different intervention periods, the shortest period
intervention (less than 1year) did not display a signiﬁcant effect for
glucose control (Z¼1.35, P>0.05). and its WMD (95% CI) was
-0.12 mmol/L (-0.20,0.05). There was a signiﬁcant effect (Z¼7.19,
P<0.05) in 1-year subgroup. The longer the intervention period was,
the higher the subtotal effect was. The pooled effect in 3 years
subgroup was the highest with WMD(95% CI)¼-0.24 mmol/L
(-0.22,0.15). When participants were divided into two groups ac-
cording to age, individuals within 40-55 years was included into
younger subgroup and all others were assigned to elderly subgroup.
No signiﬁcant subgroup pooled effects were found in younger
subgroup (Z¼1.65, P>0.05). However, in elderly subgroup, there was
a signiﬁcant effect(Z¼10.31, P<0.05). In the two groups, the subtotal
effects were -0.27(-0.60,0.05) and-0.19(-0.22,-0.15), respectively. As
for different regions, signiﬁcant heterogeneity existed among
studies conducted in America and China, but not in Europe
(I2¼47.00%). The subtotal effect was varied indifferent regions. The
studies conducted among the European population displayed a
higher subtotal effect and its WMD was -0.22, its 95% CI was (-0.27,
-0.17) with Z¼8.01 and P<0.05.
CONCLUSIONS These results indicated both exercise-only and exer-
cise-diet intervention have displayed effect on decreasing the fasting
plasma glucose, with a better results in later group. The pooled effect
was more signiﬁcant in longer intervention period, elderly age group
and European group.
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OBJECTIVES To determine the incidences of gestational diabetes
mellitus (GDM) in Shanghai in two time points (2001 and 2010)
respectively, and to further evaluate whether or not these risk factors
of GDM have changed over time.
